Valuation: Grifols SA

Market Cap 5.49B 6.29B 5.08B 4.66B 8.83B 606B 8.98B 60.6B 23.78B 296B 23.6B 23.09B 1,021B P/E 2026 *
11.9x
P/E 2027 * 8.86x
Enterprise Value 13.88B 15.88B 12.84B 11.78B 22.3B 1,531B 22.7B 153B 60.1B 749B 59.64B 58.35B 2,579B EV / Sales 2026 *
1.81x
EV / Sales 2027 * 1.67x
Free-Float
79.65%
Yield 2026 *
2.88%
Yield 2027 * 3.26%
Manager TitleAgeSince
Chief Executive Officer 57 31/03/2024
Director of Finance/CFO 49 15/09/2024
Compliance Officer 54 31/12/2013
Director TitleAgeSince
Chairman 76 24/01/2010
Director/Board Member 70 12/04/2000
Director/Board Member 62 23/05/2015
Change 5-day change 1-year change 3-year change Capi.($)
+2.18%+2.42%+23.90%-5.51% 67.6B
+0.85%-4.42%+39.25%+199.67% 51.32B
+0.94%+39.60%+39.60%+39.60% 42.97B
+0.16%-1.89%-51.35%-53.27% 40.81B
+5.92%+4.27%+63.86%-25.10% 29.12B
-7.51%-14.43%+99.97%-47.96% 27.09B
+1.36%-0.52%+70.92%+88.88% 22.99B
-2.94%+9.28%+9.66%+190.29% 21.55B
+2.15%-1.61%+58.33%+129.01% 16.38B
Average +0.35%-1.09%+39.35%+57.29% 35.54B
Weighted average by Cap. +0.66%-1.35%+33.14%+48.87%

Financials

2026 *2027 *
Net sales 7.67B 8.78B 7.1B 6.51B 12.33B 846B 12.55B 84.63B 33.21B 414B 32.96B 32.25B 1,425B 8.15B 9.32B 7.53B 6.91B 13.08B 898B 13.32B 89.85B 35.26B 439B 34.99B 34.23B 1,513B
Net income 511M 585M 473M 434M 821M 56.35B 836M 5.64B 2.21B 27.56B 2.2B 2.15B 94.94B 692M 791M 640M 587M 1.11B 76.27B 1.13B 7.63B 2.99B 37.3B 2.97B 2.91B 129B
Net Debt 8.39B 9.6B 7.76B 7.12B 13.48B 925B 13.72B 92.54B 36.31B 452B 36.04B 35.26B 1,558B 8.08B 9.24B 7.47B 6.86B 12.98B 891B 13.21B 89.1B 34.97B 436B 34.7B 33.95B 1,501B
Logo Grifols SA
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-